| 1368 |
National Cancer Institute |
Html |
en |
Breast Cancer Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for breast cancer. |
| Breast Screening Study-2 | 0.614803 |
| breast cancer deaths | 0.621624 |
| widespread mammography screening | 0.607903 |
| biennial screening mammography | 0.591767 |
| breast cancer case | 0.582361 |
| Mammography screening rates | 0.59827 |
| meaningful breast cancer | 0.581856 |
| breast biopsy | 0.585064 |
| Breast Screening Study | 0.610161 |
| digital mammography | 0.665528 |
| breast screening | 0.639247 |
| mammography | 0.707944 |
| film mammography | 0.596868 |
| Canadian National Breast | 0.584048 |
| Nijmegen breast cancer | 0.583392 |
| breast cancer treatment | 0.611216 |
| Natl Cancer Inst | 0.587118 |
| mammography service screening | 0.585616 |
| reduces breast cancer | 0.583893 |
| Breast Cancer Diagnosis | 0.59888 |
| breast cancer therapy | 0.585682 |
| invasive breast cancer | 0.614887 |
| breast tomosynthesis screening | 0.597792 |
| women | 0.639036 |
| National Breast Screening | 0.627397 |
|
| early breast cancer | 0.585311 |
| increases breast cancer | 0.597473 |
| breast cancer detection | 0.615948 |
| Breast Screening Program | 0.60752 |
| breast cancer die | 0.596834 |
| late-stage breast cancer | 0.587879 |
| significant breast cancer | 0.583394 |
| breast cancers | 0.586001 |
| Digital Screening Mammography | 0.598927 |
| mammography screening | 0.623635 |
| screening mammography | 0.613991 |
| Mammography Screening Effectiveness | 0.588634 |
| digital breast tomosynthesis | 0.604618 |
| UK breast screening | 0.596293 |
| breast cancer screening | 0.748635 |
| breast cancer risk | 0.584885 |
| reduced breast cancer | 0.582941 |
| breast cancer | 0.993291 |
| clinical breast examination | 0.595498 |
| breast cancer mortality | 0.853194 |
| breast cancer cases | 0.601413 |
| breast cancer mortality. | 0.607032 |
| full-field digital mammography | 0.586893 |
| breast cancer incidence | 0.622797 |
|
CLICK HERE |
| 1397 |
National Cancer Institute |
Html |
en |
Lymphedema (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of lymphedema, a condition in which lymph fluid builds up in tissues and causes swelling. |
| cancer treatment | 0.423589 |
| PDQ cancer information | 0.483377 |
| lymph flow | 0.481362 |
| leg | 0.408261 |
| left lymph duct | 0.48735 |
| white blood cells | 0.398624 |
| secondary lymphedema | 0.507085 |
| clinical trials | 0.422847 |
| cancer information summary | 0.440651 |
| clinical trial | 0.38593 |
| tiny lymph vessels | 0.509598 |
| breast cancer patients | 0.459436 |
| sentinel lymph node | 0.518746 |
| certified lymphedema therapists | 0.498842 |
| breast cancer survivors | 0.394173 |
| upper-body exercise | 0.39564 |
| NCI PDQ cancer | 0.395621 |
| Untreated lymphedema | 0.491735 |
| lymph nodes | 0.686068 |
| swollen area | 0.380684 |
| radiation therapy | 0.378654 |
| treatment | 0.447311 |
| Lymphedema section | 0.47523 |
| lymphedema sleeves | 0.47753 |
| severe lymphedema | 0.470942 |
|
| skin | 0.4219 |
| Cancer Information Service | 0.379239 |
| Primary lymphedema | 0.49612 |
| lymph | 0.792134 |
| body tissues | 0.403337 |
| larger lymph vessels | 0.508148 |
| Stage III lymphedema | 0.489621 |
| National Cancer Institute | 0.439823 |
| arm | 0.413813 |
| lymphedema therapist | 0.534874 |
| Palliative Care Editorial | 0.381473 |
| lymph vessels | 0.714976 |
| limb | 0.427251 |
| lymphedema | 0.932301 |
| certified lymphedema therapist | 0.527418 |
| breast cancer | 0.483638 |
| Care Editorial Board | 0.382648 |
| pressure garment | 0.387805 |
| lymphedema increases | 0.491902 |
| swollen limb | 0.388807 |
| lymph fluid | 0.457795 |
| cancer information summaries | 0.378678 |
| comprehensive cancer information | 0.377712 |
| cancer | 0.547119 |
|
CLICK HERE |
| 1479 |
National Cancer Institute |
Html |
en |
Prostate Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of prostate cancer. |
| prostate cancer warrants | 0.499797 |
| screen-detected prostate cancer | 0.525488 |
| grade prostate cancer | 0.523426 |
| Low-Risk Prostate Cancer | 0.500547 |
| Engl J Med | 0.559367 |
| advanced prostate cancer | 0.529012 |
| prostate cancer treatment | 0.512803 |
| Prostate Cancer Prostatic | 0.498893 |
| clinically localized prostate | 0.673086 |
| Int J Radiat | 0.493888 |
| metastatic prostate cancer | 0.500485 |
| Radiat Oncol Biol | 0.568418 |
| prostate cancer increases | 0.499539 |
| prostate specific antigen | 0.536475 |
| Natl Cancer Inst | 0.689089 |
| organ-confined prostate cancer | 0.499295 |
| radiation therapy | 0.50488 |
| Prostate cancer diagnosis | 0.525315 |
| prostate carcinoma | 0.533902 |
| et al. | 0.579019 |
| nonpalpable prostate cancer | 0.508262 |
| National Prostate Cancer | 0.512122 |
| Prostate Cancer section | 0.509753 |
| Prostate Cancer Outcomes | 0.519033 |
| recurrent prostate cancer | 0.502138 |
|
| castration-resistant prostate cancer | 0.500277 |
| prostate cancer eligible | 0.506835 |
| Prostate Cancer Intervention | 0.504501 |
| Prostate cancer radiation | 0.50507 |
| PUBMED Abstract | 0.502954 |
| radical prostatectomy | 0.797797 |
| Localized Prostate Cancer | 0.557914 |
| early prostate cancer | 0.559358 |
| Castration-Sensitive Prostate Cancer | 0.498217 |
| low grade prostate | 0.495809 |
| localised prostate cancer | 0.501262 |
| radical retropubic prostatectomy | 0.495282 |
| Abstract | 0.672665 |
| Clin Oncol | 0.580989 |
| Oncol Biol Phys | 0.571819 |
| prostate cancer prognosis | 0.512411 |
| Prostate Cancer Register | 0.511523 |
| prostate cancer survival | 0.523146 |
| risk prostate cancer | 0.510212 |
| prostate cancer | 0.923001 |
| Association Prostate Cancer | 0.506382 |
| prostate cancer progression | 0.524034 |
| prostate cancer recurrence | 0.538252 |
| watchful waiting | 0.496685 |
|
CLICK HERE |
| 1589 |
National Cancer Institute |
Html |
en |
Adrenocortical Carcinoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adrenocortical carcinoma. |
| treatment | 0.550891 |
| malignant tumor cells | 0.393623 |
| cancer treatment | 0.339234 |
| NCI-supported cancer | 0.325244 |
| cancer cells | 0.380323 |
| Adrenocortical Carcinoma Home | 0.328751 |
| adrenal cortex | 0.482225 |
| body | 0.41124 |
| adrenocortical carcinoma spreads | 0.336583 |
| PDQ cancer information | 0.400868 |
| adrenal medulla | 0.329784 |
| clinical trial search | 0.399161 |
| treatment clinical trials | 0.346018 |
| affected adrenal gland | 0.313913 |
| National Cancer Institute | 0.418105 |
| clinical trials | 0.816364 |
| adrenal gland | 0.62258 |
| High blood pressure | 0.300595 |
| Adrenal gland cells | 0.329473 |
| normal cells | 0.306099 |
| cancer information summary | 0.36038 |
| clinical trial | 0.576848 |
| Adrenocortical Carcinoma Treatment | 0.355819 |
|
| new treatment | 0.426441 |
| nonfunctioning adrenocortical tumor | 0.334163 |
| detailed pictures | 0.31402 |
| patients | 0.305698 |
| adrenocortical carcinoma | 0.949806 |
| Recurrent adrenocortical carcinoma | 0.379499 |
| adrenocortical carcinoma cells | 0.349105 |
| adrenal glands | 0.394752 |
| blood | 0.322073 |
| nuclear magnetic resonance | 0.302225 |
| PDQ summary | 0.318647 |
| treatment clinical trial | 0.305174 |
| NCI PDQ cancer | 0.312561 |
| Treatment Option Overview | 0.314325 |
| cancer clinical trials | 0.41336 |
| lymph nodes | 0.306574 |
| radiation therapy | 0.311431 |
| Treatment Editorial Board | 0.302427 |
| cancer | 0.760261 |
| information | 0.413368 |
| standard treatment | 0.301619 |
| adrenocortical carcinoma depend | 0.345997 |
| positron emission tomography | 0.305618 |
|
CLICK HERE |
| 1972 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de Kaposi (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma de Kaposi. |
| PDQ Tratamiento | 0.421281 |
| estadios tardÃos | 0.422639 |
| siguientes procedimientos | 0.46906 |
| linfocitos cd34 | 0.430375 |
| Physician Data Query | 0.440927 |
| pequeña cantidad | 0.415736 |
| Estados Unidos | 0.462912 |
| Kaposi causa efectos | 0.710153 |
| siguientes tipos | 0.434075 |
| vÃa oral | 0.416125 |
| rayos x | 0.425639 |
| Kaposi africano | 0.971754 |
|
| enlace drugs approved | 0.48088 |
| células cd34 | 0.490481 |
| siguientes formas | 0.418075 |
| vÃas respiratorias | 0.427366 |
| Kaposi Sarcoma | 0.792161 |
| estudio clÃnico | 0.421218 |
| National Cancer Institute | 0.409422 |
| terapia tarc | 0.47747 |
| siguientes riesgos | 0.407053 |
| siguientes pruebas | 0.484334 |
| Instituto Nacional | 0.419362 |
|
CLICK HERE |
| 2019 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o de los exámenes detección sistemática el cáncer de cuello uterino. |
| Obstet Gynecol | 0.418098 |
| cervical carcinoma | 0.403783 |
| mujeres frente | 0.403728 |
| squamous cells | 0.404736 |
| American Cancer Society | 0.40494 |
| lesion triage study | 0.403147 |
| case-control study | 0.405788 |
| cervical screening | 0.4086 |
| cervical neoplasia | 0.409268 |
| Schiffman M | 0.402549 |
| Triage Study | 0.405541 |
| Natural history | 0.403957 |
| Preventive Services Task | 0.402237 |
| citologÃa cervical simultáneas | 0.405826 |
| mild cervical dysplasia | 0.403858 |
| VPH carcinógenas | 0.40547 |
| Estados Unidos | 0.417275 |
| prueba pap | 0.411293 |
| Natl Cancer Inst | 0.410724 |
| cervical cancer | 0.523614 |
| papillomavirus infection | 0.403088 |
| única prueba | 0.403224 |
| human papillomavirus | 0.418921 |
| Cuello C | 0.403028 |
| atypical squamous cells | 0.40277 |
|
| SEER Cancer Statistics | 0.402517 |
| squamous intraepithelial lesion | 0.405593 |
| Kulasingam SL | 0.40266 |
| cervical cytology | 0.415384 |
| Cancer Facts | 0.402516 |
| lesiones nic | 0.408608 |
| VPH solas | 0.405319 |
| Pap periódicas | 0.403922 |
| abnormal screening papanicolaou | 0.402215 |
| cervical screening with | 0.406225 |
| National Cancer Institute | 0.402517 |
| Intern Med | 0.403466 |
| cervical smears | 0.405667 |
| Services Task Force | 0.402151 |
| intraepithelial lesion triage | 0.402447 |
| cervical intraepithelial neoplasia | 0.406913 |
| cuello uterino | 0.992428 |
| invasivo exhiben pruebas | 0.402524 |
| cervical cytologic | 0.405907 |
| cervical squamous | 0.403914 |
| mujeres morirán | 0.404155 |
| prueba iva | 0.403005 |
| mujeres jóvenes | 0.420213 |
| Cervical Cancer Early | 0.406229 |
|
CLICK HERE |
| 3430 |
National Cancer Institute |
Html |
es |
Vitamina D y prevención del cáncer |
Hoja informativa que resume los resultados de estudios sobre la vitamina D y la prevención del cáncer. Incluye información acerca de las recomendaciones dietéticas de vitamina D. |
| or without calcium | 0.304559 |
| pre-diagnostic circulating | 0.302687 |
| Nomura AM | 0.302611 |
| menor incidencia | 0.30287 |
| Bueno-de-Mesquita HB | 0.302697 |
| Sin embargo | 0.347217 |
| vitamina d2 | 0.359138 |
| vitamina d | 0.969991 |
| Working Group Reports | 0.305032 |
| Nutrition Examination Survey | 0.305408 |
| Dietary Reference Intakes | 0.304573 |
| Preventive Services Task | 0.304306 |
| Kotchen JM | 0.302687 |
| Instituto Nacional | 0.302694 |
| Jenab M | 0.302565 |
| IARC Working Group | 0.325138 |
| estudio vitamin | 0.304251 |
| Internal Medicine | 0.302749 |
| nested case-control study | 0.304876 |
| Calcium plus | 0.302727 |
| vitamina d3 | 0.358882 |
| rayos ultravioleta | 0.302804 |
| Academias Nacionales | 0.302714 |
| PubMed Abstract | 0.415835 |
| omega-3 trial | 0.309613 |
|
| updated meta-analysis | 0.302703 |
| Clinical Oncology | 0.303267 |
| International Journal | 0.302591 |
| cohort study | 0.30307 |
| vitamin d | 0.319766 |
| Contemporary Clinical Trials | 0.305104 |
| Endocrine-Related Cancer | 0.30602 |
| Numerosos estudios | 0.304406 |
| luz solar | 0.307463 |
| alto consumo | 0.305055 |
| primary prevention | 0.303006 |
| large randomized controlled | 0.30456 |
| siguientes consumos | 0.303025 |
| Yetley EA | 0.302569 |
| Woolcott CG | 0.302657 |
| Clinical Nutrition | 0.303564 |
| consumos dietéticos promedio | 0.306519 |
| systematic review | 0.302703 |
| Larriba MJ | 0.302545 |
| Women’s Health Initiative | 0.30465 |
| Wilkens LR | 0.302784 |
| suficiente vitamina d | 0.340884 |
| New England Journal | 0.304545 |
| Brulé D | 0.306623 |
|
CLICK HERE |
| 15907 |
National Cancer Institute |
Html |
es |
Laetrilo (amigdalina) (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer. |
| siguientes teorÃas | 0.410914 |
| suficiente información | 0.405414 |
| Centro Nacional | 0.412476 |
| Phaseolus lunatus | 0.410368 |
| New Hampshire Avenue | 0.408624 |
| Drug Administration | 0.405353 |
| NCI Best Case | 0.416678 |
| fase i | 0.407749 |
| datos bibliográficos pubmed | 0.409348 |
| largo plazo | 0.408034 |
| siguientes preguntas | 0.406283 |
| vitamina b17 | 0.411219 |
| cuáles tipos | 0.408099 |
| vitamina c | 0.408062 |
| vitamina a | 0.409071 |
| siguientes riesgos | 0.407854 |
| seguro médico | 0.405074 |
| Instituto Nacional | 0.512438 |
|
| Salud Complementaria | 0.418716 |
| Visuals Online | 0.406445 |
| siguientes resultados | 0.443523 |
| complementarias revisa | 0.408971 |
| Physician Data Query | 0.437362 |
| siguientes causas | 0.409284 |
| Estados Unidos | 0.980672 |
| enzimas pancreáticas | 0.42962 |
| Corte Suprema | 0.408891 |
| libre uso | 0.407165 |
| determinadas frutas | 0.407416 |
| página manejo | 0.406016 |
| ¿El tratamiento | 0.415719 |
| ¿Los beneficios | 0.405473 |
| juntos cam | 0.405199 |
| Series Program | 0.405225 |
| medicina complementaria | 0.651404 |
|
CLICK HERE |
| 16651 |
National Cancer Institute |
Html |
en |
Current and Alumni Fellows |
NCI and FDA collaborate to train scientists in research and research-related regulatory review. Meet the current IOTF fellows. |
| different manufacturing methods | 0.665313 |
| product quality research/review | 0.827177 |
| hematopoietic stem cell | 0.710973 |
| cancer signal transduction | 0.668322 |
| Doctoral degree | 0.684206 |
| product quality | 0.918183 |
| challenging supervisory roles | 0.648276 |
| Oncology Task Force | 0.8356 |
| oncology drug products | 0.690726 |
| long term goal | 0.660419 |
| Review Team Leader | 0.655657 |
| Biological Sciences | 0.682061 |
| gene therapy products | 0.670826 |
| new therapeutic targets | 0.828038 |
| DNA repair proteins | 0.657265 |
| Dr. Sanduja | 0.871474 |
| overall research | 0.68067 |
| invaluable training experience | 0.676806 |
| NCI-FDA Interagency Oncology | 0.711009 |
| oncology product research | 0.767652 |
| drug development process | 0.675006 |
| cell therapy products | 0.686143 |
| experienced product quality | 0.672111 |
| Mixed Lineage Leukemia | 0.669398 |
| intramural FDA training/courses | 0.684636 |
|
| various FDA centers | 0.683563 |
| regulatory sciences | 0.680019 |
| NCI-NIH-FDA Interagency Oncology | 0.692697 |
| post-doctoral training | 0.683105 |
| mesenchymal stromal cells | 0.685647 |
| breast cancer metastasis | 0.669833 |
| product quality reviewer | 0.814583 |
| South Carolina | 0.648309 |
| IOTF fellowship | 0.939794 |
| current fellows | 0.684819 |
| acute myeloid leukemia | 0.671421 |
| Task Force Fellowship | 0.822403 |
| full-time product quality | 0.810197 |
| oncology research experience | 0.714771 |
| National Cancer Institute | 0.698441 |
| cancer stem cells | 0.955681 |
| Interagency Oncology Task | 0.843679 |
| mammary stem cell | 0.68776 |
| quality research/review fellow | 0.82871 |
| breast cancer stem | 0.695251 |
| Dr. Ergen | 0.910594 |
| Jawaharlal Nehru University | 0.669149 |
| pre-clinical cancer models | 0.702445 |
| national regulatory conferences | 0.67238 |
|
CLICK HERE |
| 16717 |
National Cancer Institute |
Html |
en |
Cancer Clinical Trials at the National Institutes of Health Clinical Center |
Information about cancer clinical trials at the NIH Clinical Center in Bethesda, Maryland. |
| cancer treatment | 0.534356 |
| better understanding | 0.369317 |
| clinical program | 0.414778 |
| eligibility criteria | 0.37194 |
| health insurance | 0.371915 |
| novel cancer treatment | 0.457878 |
| International patients | 0.371646 |
| health care provider | 0.502194 |
| clinical trial experience | 0.462664 |
| clinical teams | 0.407146 |
| NIH physicians | 0.420773 |
| Patients page | 0.377331 |
| NCI clinic | 0.401655 |
| open trials | 0.377021 |
| in-house cancer center | 0.477433 |
| Patient Self-Referral Form | 0.427003 |
| unique hospital | 0.366285 |
| clinical trials | 0.623234 |
| treatment services | 0.380122 |
| health care providers | 0.57596 |
| approach fosters interaction | 0.418119 |
| National Institutes | 0.375152 |
| clinical trial | 0.527278 |
| contact information | 0.370247 |
| CCR clinical trials | 0.482065 |
|
| patients | 0.409802 |
| cancer patients | 0.399962 |
| standard treatment options | 0.440025 |
| trial’s eligibility | 0.38116 |
| related research | 0.378808 |
| patient care units | 0.440886 |
| United States | 0.412623 |
| largest hospital | 0.37768 |
| cancer research | 0.528759 |
| NIH Clinical Center | 0.949828 |
| National Cancer Institute | 0.460111 |
| NCI research team | 0.453825 |
| Clinical Research Referral | 0.467688 |
| Developmental Therapeutics Clinic | 0.698646 |
| advanced cancer | 0.386466 |
| trial information | 0.38805 |
| new treatments | 0.372193 |
| NCI principal investigator | 0.437174 |
| patient treatment plans | 0.430619 |
| compassionate doctors | 0.368527 |
| care specialists | 0.389607 |
| medical care | 0.431584 |
| scientific resources | 0.368533 |
| trial summary | 0.38584 |
|
CLICK HERE |